What do autoinflammatory syndromes teach about common cutaneous diseases such as Pyoderma Gangrenosum? A commentary

Dermatologic Clinics

Volumn 31, Issue 3, 2013, Pages 427-435

  Butler, Daniel ^a   Shinkai, Kanade ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoinflammation; Cryopyrin associated periodic syndrome; Deficiency of interleukin 1 receptor agonist; Familial Mediterranean fever; Neutrophilic dermatoses; Pyoderma gangrenosum; Pyogenic arthritis syndrome

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

AUTOINFLAMMATORY DISEASE; CCR61+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CXCL81+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; INFECTION; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SUPPURATIVE HIDRADENITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL;

AUTOINFLAMMATION; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME; DEFICIENCY OF INTERLEUKIN 1 RECEPTOR AGONIST; FAMILIAL MEDITERRANEAN FEVER; NEUTROPHILIC DERMATOSES; PYODERMA GANGRENOSUM; PYOGENIC ARTHRITIS SYNDROME;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEUTROPENIA; PYODERMA GANGRENOSUM; SYNDROME;

EID: 84879889244     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2013.04.004     Document Type: Review

References (38)

1. Ahronowitz I., Harp J., Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012, 13(3):191-211.
2. Brydges S., Kastner D.L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 2006, 305:127-160.
3. Bennett M.L., Jackson J.M., Jorizzo J.L., et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000, 79(1):37-46.
4. Farasat S., Aksentijevich I., Toro J.R. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008, 144(3):392-402.
5. Simon A., van der Meer J.W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007, 292(1):R86-R98.
6. Brenner M., Ruzicka T., Plewig G., et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009, 161(5):1199-1201.
7. Tofteland N.D., Shaver T.S. Clinical efficacy of etanercept for treatment of PAPA syndrome. JClin Rheumatol 2010, 16(5):244-245.
8. Demidowich A.P., Freeman A.F., Kuhns D.B., et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012, 64(6):2022-2027.
9. Aksentijevich I., Masters S.L., Ferguson P.J., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. NEngl J Med 2009, 360(23):2426-2437.
10. Shaw M.H., Reimer T., Kim Y.G., et al. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 2008, 20(4):377-382.
11. Church L.D., Cook G.P., McDermott M.F. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008, 4(1):34-42.
12. Ting J.P., Kastner D.L., Hoffman H.M. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006, 6(3):183-195.
13. Contassot E., Beer H.D., French L.E. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly 2012, 142:w13590.
14. Shinkai K., Kilcline C., Connolly M.K., et al. The pyrin family of fever genes: unmasking genetic determinants of autoinflammatory disease. Arch Dermatol 2005, 141(2):242-247.
15. Zeft A.S., Spalding S.J. Autoinflammatory syndromes: fever is not always a sign of infection. Cleve Clin J Med 2012, 79(8):569-581.
16. Shoham N.G., Centola M., Mansfield E., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci US A 2003, 100(23):13501-13506.
17. Yu J.W., Fernandes-Alnemri T., Datta P., et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007, 28(2):214-227.
18. Shenefelt P.D. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996, 57(5):315-319.
19. Ah-Weng A., Langtry J.A., Velangi S., et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005, 30(6):669-671.
20. Hsiao J.L., Antaya R.J., Berger T., et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010, 146(11):1265-1270.
21. Braun-Falco M., Kovnerystyy O., Lohse P., et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. JAm Acad Dermatol 2012, 66(3):409-415.
22. Fleischmann R. Anakinra in the treatment of rheumatic disease. Expert Rev Clin Immunol 2006, 2(3):331-340.
23. Krause K., Weller K., Stefaniak R., et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012, 67(7):943-950.
24. Guenova E., Teske A., Fehrenbacher B., et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011, 147(10):1203-1205.
25. Goldminz A.M., Botto N.C., Gottlieb A.B. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. JAm Acad Dermatol 2012, 67(5):e237-e238.
26. Fahmy M., Ramamoorthy S., Hata T., et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012, 107(5):794-795.
27. Uhara H., Saida T., Nakazawa H., et al. Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor. JAm Acad Dermatol 2008, 59(2 Suppl 1):S10-S12.
28. Draper B.K., Robbins J.B., Stricklin G.P. Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim. JAm Acad Dermatol 2005, 52(5):901-905.
29. Kawakami T., Ohashi S., Kawa Y., et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004, 140(5):570-574.
30. Spiekermann K., Roesler J., Emmendoerffer A., et al. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 1997, 11(4):466-478.
31. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). JAm Acad Dermatol 1994, 31(4):535-556. [quiz: 557-60].
32. Hasegawa M., Sato S., Nakada M., et al. Sweet's syndrome associated with granulocyte colony-stimulating factor. Eur J Dermatol 1998, 8(7):503-505.
33. Bidyasar S., Montoya M., Suleman K., et al. Sweet syndrome associated with granulocyte colony-stimulating factor. JClin Oncol 2008, 26(26):4355-4356.
34. Reuss-Borst M.A., Pawelec G., Saal J.G., et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993, 84(2):356-358.
35. Keller M., Spanou Z., Schaerli P., et al. Tcell-regulated neutrophilic inflammation in autoinflammatory diseases. JImmunol 2005, 175(11):7678-7686.
36. Fischer-Stabauer M., Boehner A., Eyerich S., et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol 2012, 22(6):781-784.
37. Nord K.M., Pappert A.S., Grossman M.E. Pyodermagangrenosum-like lesions in leukocyte adhesion deficiency I treated with intravenous immunoglobulin. Pediatr Dermatol 2011, 28(2):156-161.
38. Nesterovitch A.B., Gyorfy Z., Hoffman M.D., et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol 2011, 178(4):1434-1441.